Biofrontera announces that on February 24 it has published the audited annual statement for 2008
(Thomson Reuters ONE) -
Biofrontera AG / Biofrontera announces that on February 24 it has published the audited annual statement for 2008 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany - Biofrontera (DSE: B8F) publishes that Warth & Klein AG
Wirtschaftsprüfungsgesellschaft, the auditor appointed by Biofrontera's
shareholder meeting, has granted the audit report for the finances of 2008 which
had already been published in 2009. Previously the auditors could only announce
the audit report since major finance and restructuring measures initiated by the
company had not been fully completed.
In this respect the company has in the meantime reached the following goals,
based on which the audit report has now been granted:
- Capital increase of over 7 mln. euro through the placement of new shares
- Restructuring of the convertible bond
- Based on these steps, a pronounced improvement of the equity capital
- Completion and payment of both phase III studies for the drug candidate BF-200
ALA
- Completion and payment of the phase II study of the drug candidate BF-derm1
- Market introduction of Belixos® cream for medical skin care accompanying
therapy, f.i. in atopic dermatitis or psoriasis
- Cost reduction measures
Instantly following the completion of the auditing for 2008, the financial
report of 2009 is being audited. Approval by the supervisory board is expected
before the end of March 2010.
In the capital increases in 2009, new shares were generated which are currently
listed on the Düsseldorf and Berlin trading floor (DE000A0XFUG4 und
DE000A1CRN13), next to the original share class trading on the Düsseldorf
regulated market, most other German stock markets and on Xetra (DE0006046113).
To combine these three share classes in the regulated market, the company has
last year mandated a bank, which is currently preparing the required prospectus
together with a law firm and the Biofrontera management.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical products in
the area of dermatology. The company is characterized by a broad, relatively
close to the market product portfolio. Biofrontera is listed in the regulated
market of the Düsseldorf stock exchange under the symbol B8F and the ISIN
DE0006046113.
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these
forward-looking statements to reflect future events or developments.
For further information please contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
The press release can be downloaded from the following link:
[HUG#1388957]
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;
Press Release (PDF): http://hugin.info/136349/R/1388957/347209.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.02.2010 - 04:33 Uhr
Sprache: Deutsch
News-ID 1010712
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leverkusen
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera announces that on February 24 it has published the audited annual statement for 2008
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
